Boston Scientific (NYSE:BSX) said today that it plans to buy back up to $1 billion worth of its senior debt.
The debt included in the tender offer is made up of $450 million in 4.125% notes due 2023; $1.0 billion in 4.0% notes due 2028; $750 million in 3.85% notes due 2025; and $500 million in 3.375% notes due 2022, the Marlborough, Mass.-based medical device maker said.
The tender is slated to expire at midnight Eastern Nov. 19; debt owners who tender their notes before 5 p.m. Nov. 4 are eligible for an extra it $30 per $1,000 worth of principal, Boston Scientific said.
Barclays Capital, BofA Securities and Goldman Sachs are the lead dealer managers for the offer, with D.F. King as information agent and tender agent.